About Syntonix Pharmaceuticals
Syntonix Pharmaceuticals is a Healthcare company based in Waltham (United States) founded in 1999, and was acquired by Biogen in January 2007. It operates as a therapeutic proteins for chronic diseases like hemophilia are developed. Its chief executive is James C Mullen. The company was acqui-hired. Its focus areas include Life Sciences, Rare Diseases, Drugs and Hematology. Its competitors include Editas Medicine, GBT, LogicBio, Modus Therapeutics and Kedrion and 2 more; 6 of its 7 listed competitors have raised funding.
Company details
Syntonix Pharmaceuticals was founded in 1999 and is based in Waltham, United States. Biopharmaceuticals are developed by the company for chronic conditions such as hemophilia, anemia, and autoimmune disorders. Core technologies are utilized to produce long-acting SynFusion drugs, which allow for less frequent administration through inhalation or injection. Proteins, peptides, and antibodies are advanced via internal development and collaborations with biotechnology and pharmaceutical partners in the sector.
- Headquarters Waltham, United States
- Stage Acquired
- SectorsHealthcare
- Website syntnx.com
- Social LinkedIn
- Acquired by Biogen (Jan 2007)
Investors in Syntonix Pharmaceuticals
Syntonix Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Biogen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Therapies for neurodegenerative and immunology disorders are developed. | 1978 | biogen.com | Cambridge, United States |
Investor details for Syntonix Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Syntonix Pharmaceuticals
1 people are tracked at Syntonix Pharmaceuticals (1 in leadership).
| Name | Role | Group |
|---|---|---|
James C Mullen | CEO | Leadership |
Complete people profiles for Syntonix Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Syntonix Pharmaceuticals
2 dated milestones of Syntonix Pharmaceuticals across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Syntonix Pharmaceuticals is founded.
- Exit Acquired by Biogen.
Competitors of Syntonix Pharmaceuticals
Syntonix Pharmaceuticals has 7 listed competitors in our database, 6 of them funded. They include Editas Medicine, GBT, LogicBio, Modus Therapeutics and Kedrion, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| editasmedicine.com | 2013 | Cambridge, United States | $210M | 257 | Therapeutics for rare genetic diseases are developed using CRISPR technology. | |
| gbt.com | 2011 | San Francisco, United States | $177.4M | 457 | Small molecules are developed for sickle cell disease treatment. | |
| logicbio.com | 2013 | Lexington, United States | $49M | 62 | Viral vectors are developed for genetic and infectious disease treatments. | |
| modustx.com | 2011 | Stockholm, Sweden | $22.88M | – | Polysaccharide-based drug for Sickle Cell Disease treatment is developed. | |
| kedrion.com | 2001 | Barga, Italy | $188.56M | – | Plasma-derived therapies are developed for hemophilia and immune deficiencies. | |
| dova.com | 2016 | Durham, United States | $10M | – | Drug candidates for rare diseases are acquired, developed, and commercialized. | |
| cyclerion.com | 2018 | Cambridge, United States | – | 32 | Therapies for sickle cell disease and diabetic nephropathy are developed. |
Detailed competitors of Syntonix Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Syntonix Pharmaceuticals
Websites that share an audience with Syntonix Pharmaceuticals (syntnx.com).
Websites whose visitors overlap most with Syntonix Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
oscient.com | oscient.com | 100% | – | – | – |
| novabiomedical.com | 100% | 16.5K | #1,303,115 | View details | |
extech.com | extech.com | 100% | – | – | – |
| confluentsurgical.com | 100% | – | – | View details | |
mmccinc.com | mmccinc.com | 100% | – | – | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 9 similar websites and full traffic analytics for Syntonix Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 9 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Rare Diseases
10 companies that operate in the same segment as Syntonix Pharmaceuticals (Rare Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Solutions for genetic diseases are developed using CRISPR-Cas9 genome editing. | 2013 | Basel, Basel-stadt, Switzerland | USD 127 M | USD 37.31 M | 393 | |
Gene therapies for rare diseases are developed to treat patients. | 2020 | Columbus, Ohio, United States | USD 250 M | – | – | |
Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases | 2015 | Cambridge, Massachusetts, United States | USD 114.67 M | – | 45 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
RNA interference-based therapeutics are developed for multiple disorders. | 2002 | Cambridge, Massachusetts, United States | USD 17 M | USD 3.71 B | 2,230 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Therapies for gastrointestinal diseases are developed by Phathom Pharmaceuticals. | 2019 | Menlo Park, California, United States | USD 90 M | USD 175.11 M | 427 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Syntonix Pharmaceuticals
Syntonix Pharmaceuticals was founded in 1999.
Syntonix Pharmaceuticals is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
James C Mullen is the current CEO of Syntonix Pharmaceuticals.
Syntonix Pharmaceuticals was founded in 1999 and is based in Waltham, United States. Biopharmaceuticals are developed by the company for chronic conditions such as hemophilia, anemia, and autoimmune disorders. Core technologies are utilized to produce long-acting SynFusion drugs, which allow for less frequent administration through inhalation or injection. Proteins, peptides, and antibodies are advanced via internal development and collaborations with biotechnology and pharmaceutical partners in the sector.
Syntonix Pharmaceuticals's top competitors include GBT, Editas Medicine and Kedrion.
Syntonix Pharmaceuticals has 1 investor. Key investors include Biogen.
Yes. Syntonix Pharmaceuticals was acquired by Biogen in January 2007.